# Novartis plans $23B investment in US manufacturing and R&D

Novartis announced a $23 billion investment over 5 years to expand its US manufacturing and R&D footprint, including 7 new facilities and expansions at 3 existing sites, creating nearly 1,000 jobs at Novartis.

- Type: Investment
- Announced: 2025-04-10
- Where: United States (multiple sites including San Diego, CA; Indianapolis, IN; Millburn, NJ; Carlsbad, CA; Florida; Texas), United States
- Value: $23.0B
- Jobs: 1,000
- Status: announced
- Products: pharmaceuticals, active pharmaceutical ingredients, biologics, radioligand therapy

## Companies

- [Novartis](https://endata.com/companies/32041.md)

## Sources

- [novartis.com](https://www.novartis.com/us-en/news/media-releases/novartis-plans-expand-its-us-based-manufacturing-and-rd-footprint-total-investment-23b-over-next-5-years), 2025-04-10: "Today, Novartis, a leading global innovative medicines company, announced a planned $23 billion investment over 5 years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the United States."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.